Kidnry Int:肾病综合征的新机制!

2017-05-13 MedSci MedSci原创

肾小球足细胞中的Rac1,一种小GTP酶,其超激活涉及了家族性蛋白尿病的发病机制。然而,Rac1在获得性肾病综合征中的作用是未知的。为了获得这方面的直观见解,Robins R等研究者产生了一种转基因小鼠模型,表明多西环素诱导型组织型活性形式的Rac1(CA-Rac1)在足细胞中表达。不管拷贝数如何,蛋白尿在五天内迅速发生,组织学类似于微小病变。蛋白尿的程度和严重程度取决于转基因拷贝数。多西环素戒断

肾小球足细胞中的Rac1,一种小GTP酶,其超激活涉及了家族性蛋白尿病的发病机制。然而,Rac1在获得性肾病综合征中的作用是未知的。

为了获得这方面的直观见解,Robins R等研究者产生了一种转基因小鼠模型,表明多西环素诱导型组织型活性形式的Rac1(CA-Rac1)在足细胞中表达。

不管拷贝数如何,蛋白尿在五天内迅速发生,组织学类似于微小病变。蛋白尿的程度和严重程度取决于转基因拷贝数。

多西环素戒断后,蛋白尿完全消失(一份)或几乎完全(两份)消失。

经过一个月的多西霉素治疗后,双拷贝的小鼠发展出类似于局灶性节段性肾小球硬化(FSGS)的肾小球硬化,其具有表达转基因的足细胞的尿液脱落。 

P38 MAPK在CA-Rac1诱导的足细胞中被激活,而p38抑制剂可以减弱蛋白尿、足细胞的损失以及肾小球硬化。

在培养的小鼠足细胞中,Rac1的活化降低了对层粘连蛋白的粘附性并诱导β1整联蛋白的再分布,并且两者都被p38抑制剂部分逆转。

通过免疫荧光观察,来自具有微小病变和特发性FSGS患者的肾活检中可以发现足细胞中的Rac1活化,而来自相同患者的血清在培养的人足细胞中也激活Rac1。

因此,足细胞中Rac1的激活导致从微小病变到FSGS的疾病范围,这是由于部分依赖于p38-MAPK的肾小球基底膜的足细胞分离。

原始出处:
Robins R, Baldwin C, et al. Rac1 activation in podocytes induces the spectrum of nephrotic syndrome. Kidney Int. 2017 May 5. pii: S0085-2538(17)30200-4. doi: 10.1016/j.kint.2017.03.010.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1430814, encodeId=d5e61430814e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon May 15 06:54:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198083, encodeId=7d61198083a4, content=好的!感谢分享一下!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun May 14 20:36:48 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197941, encodeId=7b7019e941c5, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun May 14 10:45:05 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197882, encodeId=db4319e88233, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJicFGXtYqfjGiaibNdjOiaRgkexnXiciaDeXaLiaKicovcicDugdYwRPSnQj3FlfXBwVLB5ANB9PGFyB0kraQ/0, createdBy=35b01663265, createdName=1ddf3e1dm99(暂无匿称), createdTime=Sun May 14 08:34:19 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197785, encodeId=959d19e785c1, content=学习了新知识,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun May 14 06:45:36 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1430814, encodeId=d5e61430814e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon May 15 06:54:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198083, encodeId=7d61198083a4, content=好的!感谢分享一下!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun May 14 20:36:48 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197941, encodeId=7b7019e941c5, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun May 14 10:45:05 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197882, encodeId=db4319e88233, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJicFGXtYqfjGiaibNdjOiaRgkexnXiciaDeXaLiaKicovcicDugdYwRPSnQj3FlfXBwVLB5ANB9PGFyB0kraQ/0, createdBy=35b01663265, createdName=1ddf3e1dm99(暂无匿称), createdTime=Sun May 14 08:34:19 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197785, encodeId=959d19e785c1, content=学习了新知识,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun May 14 06:45:36 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
    2017-05-14 laymankey

    好的!感谢分享一下!!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1430814, encodeId=d5e61430814e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon May 15 06:54:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198083, encodeId=7d61198083a4, content=好的!感谢分享一下!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun May 14 20:36:48 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197941, encodeId=7b7019e941c5, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun May 14 10:45:05 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197882, encodeId=db4319e88233, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJicFGXtYqfjGiaibNdjOiaRgkexnXiciaDeXaLiaKicovcicDugdYwRPSnQj3FlfXBwVLB5ANB9PGFyB0kraQ/0, createdBy=35b01663265, createdName=1ddf3e1dm99(暂无匿称), createdTime=Sun May 14 08:34:19 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197785, encodeId=959d19e785c1, content=学习了新知识,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun May 14 06:45:36 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
    2017-05-14 1ddf0692m34(暂无匿称)

    学习了,很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1430814, encodeId=d5e61430814e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon May 15 06:54:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198083, encodeId=7d61198083a4, content=好的!感谢分享一下!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun May 14 20:36:48 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197941, encodeId=7b7019e941c5, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun May 14 10:45:05 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197882, encodeId=db4319e88233, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJicFGXtYqfjGiaibNdjOiaRgkexnXiciaDeXaLiaKicovcicDugdYwRPSnQj3FlfXBwVLB5ANB9PGFyB0kraQ/0, createdBy=35b01663265, createdName=1ddf3e1dm99(暂无匿称), createdTime=Sun May 14 08:34:19 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197785, encodeId=959d19e785c1, content=学习了新知识,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun May 14 06:45:36 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
    2017-05-14 1ddf3e1dm99(暂无匿称)

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1430814, encodeId=d5e61430814e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon May 15 06:54:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198083, encodeId=7d61198083a4, content=好的!感谢分享一下!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun May 14 20:36:48 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197941, encodeId=7b7019e941c5, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun May 14 10:45:05 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197882, encodeId=db4319e88233, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJicFGXtYqfjGiaibNdjOiaRgkexnXiciaDeXaLiaKicovcicDugdYwRPSnQj3FlfXBwVLB5ANB9PGFyB0kraQ/0, createdBy=35b01663265, createdName=1ddf3e1dm99(暂无匿称), createdTime=Sun May 14 08:34:19 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197785, encodeId=959d19e785c1, content=学习了新知识,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun May 14 06:45:36 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
    2017-05-14 杨利洪

    学习了新知识,提高了

    0

相关资讯

日本临床实践指南:肾病综合征(中文版)

2016年4月,日本肾脏病学会(JSN)发布了肾病综合症最新临床实践指南,共涉及4大部分内容,分别为:发病机制,诊断,流行病学和预后,治疗。其中针对肾病综合症的诊断和治疗,共涉及40个临床问题,并针对这些临床问题提出推荐意见。 证据水平 1级:系统综述/荟萃分析 2级:至少有一项随机对照临床试验(RCT) 3级:无RCT

Lancet:利妥昔单抗可抑制难治性肾病综合征复发

日本一个研究团队在新一期《柳叶刀》杂志网络版上发表成果说,他们实施的临床试验显示,通常用作抗癌药的“利妥昔单抗”可有效抑制难治性肾病综合征复发。 肾脏承担着过滤血液、形成尿液的任务,而难治性肾病综合征患者由于肾功能障碍导致蛋白尿,会出现脸部和手脚浮肿。该病最终可能发展为慢性肾衰竭,甚至威胁生命。 目前常用的类固醇疗法虽能有效缓解蛋白尿,但一旦停药或减少药量,半数患者会复发。而且对于小儿患者来说

JAMA:男孩脱发与肾病综合症病例报道

5 岁男孩出现局限性的头皮脱发。2周前,首先出现的症状是头皮小面积的红斑,随后范围增大伴随脱发。有轻度瘙痒不伴疼痛。他没有使用任何护发产品或头皮外用剂。His only medical history was 他唯一的病史是肾病综合征,在过去2年里口服强的松(2.5mg每天)和环孢霉素(70mg每天)。家中还有一只猫。经过检测,重要指标正常。头皮上有4厘米大小的肿胀红斑,脱发,硬结,右额叶头皮脓疱